1. Pembrolizumab-induced vasculitis demonstrated by FDG-PET/CT
- Author
-
Tuan Vu, BS, Sophia R. O'Brien, MD, Shawn X. Ma, MD, Karthik M. Sundaram, MD, PhD, and Austin R. Pantel, MD, MSTR
- Subjects
PET imaging ,FDG ,Vasculitis ,Pembrolizumab ,Immune checkpoint inhibitors ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
A 76-year-old man with a history of malignant pleural mesothelioma treated with pembrolizumab underwent FDG-PET/CT for restaging. The images demonstrated FDG uptake overlying the right hepatic and splenic artery, which were new from the previous FDG-PET/CT 2.5 years prior before the patient started pembrolizumab, suspicious for vasculitis. A follow-up MRI supported the diagnosis with evidence of celiac, splenic, common hepatic, and right hepatic artery involvement. Pembrolizumab was discontinued and the patient received a short course of oral glucocorticoids. Subsequent FDG-PET/CT performed 14 months after initiation of treatment for vasculitis demonstrated resolution of vasculitis. Immune checkpoint inhibitors can cause vasculitis, which can be recognized on FDG-PET/CT and lead to appropriate treatment.
- Published
- 2024
- Full Text
- View/download PDF